Next Article in Journal
New Protein-Coated Silver Nanoparticles: Characterization, Antitumor and Amoebicidal Activity, Antiproliferative Selectivity, Genotoxicity, and Biocompatibility Evaluation
Previous Article in Journal
Nanoporous Silica Entrapped Lipid-Drug Complexes for the Solubilization and Absorption Enhancement of Poorly Soluble Drugs
Previous Article in Special Issue
Redox-Responsive Nanocarrier for Controlled Release of Drugs in Inflammatory Skin Diseases
Open AccessReview

Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems

by 1,2,* and 3,4,*
1
Nanotechnology Centre, CEET, VSB—Technical University of Ostrava, 17. listopadu 2172/15, 708 00 Ostrava-Poruba, Czech Republic
2
Centre ENET, CEET, VSB—Technical University of Ostrava, 17. listopadu 2172/15, 708 00 Ostrava-Poruba, Czech Republic
3
Department of Analytical Chemistry, Faculty of Natural Sciences, Comenius University, Ilkovicova 6, 842 15 Bratislava, Slovakia
4
Division of Biologically Active Complexes and Molecular Magnets, Regional Centre of Advanced Technologies and Materials, Czech Advanced Technology and Research Institute, Palacky University, Slechtitelu 27, 783 71 Olomouc, Czech Republic
*
Authors to whom correspondence should be addressed.
Pharmaceutics 2021, 13(1), 64; https://doi.org/10.3390/pharmaceutics13010064 (registering DOI)
Received: 6 December 2020 / Revised: 2 January 2021 / Accepted: 4 January 2021 / Published: 6 January 2021
Inflammatory diseases, whether caused by excessive stress on certain tissues/parts of the body or arising from infections accompanying autoimmune or secondary diseases, have become a problem, especially in the Western world today. Whether these are inflammations of visceral organs, joints, bones, or the like, they are always a physiological reaction of the body, which always tries to eradicate noxious agents and restore tissue homeostasis. Unfortunately, this often results in damage, often irreversible, to the affected tissues. Nevertheless, these inflammatory reactions of the body are the results of excessive stress, strain, and the generally unhealthy environment, in which the people of Western civilization live. The pathophysiology and pathobiochemistry of inflammatory/autoimmune processes are being studied in deep detail, and pharmaceutical companies are constantly developing new drugs that modulate/suppress inflammatory responses and endogenous pro-inflammatory agents. In addition to new specifically targeted drugs for a variety of pro-inflammatory agents, a strategy can be found for the use of older drugs, which are formulated into special nanodrug delivery systems with targeted distribution and often modified release. This contribution summarizes the current state of research and development of nanoformulated anti-inflammatory agents from both conventional drug classes and experimental drugs or dietary supplements used to alleviate inflammatory reactions. View Full-Text
Keywords: drug delivery systems; nanoformulations; nanoparticles; anti-inflammatory drugs; experimental drugs; inflammation drug delivery systems; nanoformulations; nanoparticles; anti-inflammatory drugs; experimental drugs; inflammation
Show Figures

Figure 1

MDPI and ACS Style

Placha, D.; Jampilek, J. Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems. Pharmaceutics 2021, 13, 64.

AMA Style

Placha D, Jampilek J. Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems. Pharmaceutics. 2021; 13(1):64.

Chicago/Turabian Style

Placha, Daniela; Jampilek, Josef. 2021. "Chronic Inflammatory Diseases, Anti-Inflammatory Agents and Their Delivery Nanosystems" Pharmaceutics 13, no. 1: 64.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop 无码中文有码中文人妻中文,男人的天堂AV国产在线,亚洲色图,国产精品人妻在线观看,国产九九自拍亚洲